Erbitux 100mg/20mg IV

Frequently asked questions

• Onset of action

  The amount of time required for this medicine to show its action is not clinically established.

• Duration of Effect

  The amount of time for which this medicine remains active in the body is not clinically established.

• Safe with Alchohol?

  Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

• Is it habit forming?

  No habit-forming tendencies were reported.

• Usage in pregnancy?

  This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine.

• Usage while breast-feeding?

  This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine. Your doctor may advise you to discontinue breastfeeding for a specific period of time or prescribe an alternative medicine based on your clinical condition.

• Allergy

  This medicine is not recommended for use in patients with a known allergy to Erbitux Injection 100 mg 1 Vial or any other inactive ingredients present along with it.

• Pregnancy

  This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine.

• Breast-feeding

  This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine. Your doctor may advise you to discontinue breastfeeding for a specific period of time or prescribe an alternative medicine based on your clinical condition.

• Infusion related reactions

  This medicine has been associated with severe infusion-related reactions, characterized by symptoms such as fever, chills, rigors, low blood pressure, hives, swelling, etc. The onset of these reactions usually ranges from 30 minutes to 2 hours after starting the first intravenous infusion. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary in some cases based on the clinical condition of the patient.

• Skin reactions

  Use of this medicine may increase the risk of severe skin reactions. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary in some cases based on the clinical condition of the patient. Treatment may be discontinued in case of severe skin reactions.

• Infections

  This medicine should be used with caution due to the increased risk of severe and potentially life-threatening infections occurring due to bone marrow suppression. Report any unusual symptoms such as a fever, diarrhea, sore throat, pain or burning during urination, etc. to the doctor immediately. Close monitoring of clinical condition, dose adjustments, or replacement with a suitable alternative may be necessary in some cases.

• Electrolyte disturbances

  This medicine should be used with caution due to the increased risk of electrolyte depletion especially magnesium levels. Decreased Potassium and Calcium levels have also been reported with this medicine. Close monitoring of clinical condition, appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary in some cases.

• Lung toxicity

  This medicine may increase the risk of toxic effects on the lungs and could lead to respiratory failure. The lung toxicity is dose-related and close monitoring of lung function is recommended during the therapy with this medicine. Any symptoms of lung toxicity should be informed to the doctor on priority. The treatment should be discontinued if such symptoms appear.

• Cardiovascular disorders

  This medicine should be used with extreme caution in patients suffering from diseases of the heart due to the increased risk of worsening of the patient’s condition. Close monitoring of heart function and vital signs is recommended for such patients. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition.

• Eye disorders

  This medicine should be used with extreme caution in patients with eye disorders due to the increased risk of worsening of the patient’s condition. Close monitoring is recommended for such patients. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition.

• Use in Children

  This medicine is not recommended for use in patients below 18 years of age since the safety and efficacy of use are not clinically established.

• Contraception

  Use of this medicine may increase the risk of harm to the unborn baby in pregnant women. Effective contraception is advised for the women with the childbearing potential to avoid such risks. Birth controls should be administered while receiving this medicine and for 2 months post-therapy to prevent the pregnancy.